

RECEIVED 44 14 -3

NOV 20 2003

TECH CENTER 1600/2900

EXPRESS MAIL NO.: EV 335 857 684 US 1648

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bolognesi *et al.*

Confirmation No.: 3907

Application No.: 10/071,349

Group Art Unit: 1648

Filed: February 6, 2002

Examiner: To be assigned

For: SUPPRESSOR OF HIV REPLICATION
AND TRANSCRIPTION

Attorney Docket No.: 7872-087-999

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references known by Applicants or their attorneys to be material to patentability of the claimed invention, Attorneys for Applicants hereby direct the Examiner's attention to references A01-A06, B01-B03 and C01-C78, which are listed on the accompanying Revised Form PTO-1449.

The above-identified application is a continuation of U.S. Patent Application No. 09/527,320, filed March 16, 2000, now U.S. Patent No. 6,528,308. A copy of References A01-A04, B01-B03, C01, C04-C06, C14, C16-C19, C21, C24-C29, C31, C33-34, C37, C39-C40, C43, C45-46, C52-55, C61, C63, C71-72 and C74-C75 are of record in the file history of the above-cited parent application. Therefore, pursuant to 37 C.F.R. § 1.98(d), copies of these references are not submitted herewith. However, should the Examiner prefer, copies of any of the listed references will be made available to the Examiner upon request. Legible copy of each of references A05-06, C02-03, C07-C13, C15, C20, C22-C23, C30, C32, C35-C36, C38, C41-C42, C44, C47-51, C56-C60, C62, C64-C70, C73, C76-C78 are submitted herewith.

Identification of the above-listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the instant application. Consequently, Applicants respectfully decline to use Form

PTO-1449 since that form identifies all references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "Revised Form PTO-1449" entitled "List of References Cited."

Applicants respectfully request that the Examiner review each of the references identified on the attached Revised Form PTO-1449, and that the references be made of record in the file history of the above-captioned application.

This Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits; therefore, pursuant to 37 C.F.R. § 1.97(b)(3) no fee is believed due. However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

By: Stephane S. Sall, Reg. No. 43,171

Date November 12, 2003


Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

RECEIVED

Sheet 1 of 4

Express Mail No.: EV 335 857 684 US



NOV 20 2003

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

7872-087-999

APPLICATION NO

10/071,349

APPLICANT

Bolognesi et al.

FILING DATE

February 6, 2002

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,464,933	11/07/95	Bolognesi et al.			
	A02	5,656,480	08/12/97	Wild et al.			
	A03	5,627,023	05/06/97	Bolognesi et al.			
	A04	5,861,490	06/06/95	Bolognesi et al.			
	A05	5,814,519	9/29/98	Bolognesi et al.			
	A06	5,196,524	3/23/93	Gustafson et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	B01	WO 99/59615	11/25/99	PCT			
	B02	WO 96/19495	07/27/96	PCT			
	B03	WO 94/28920	11/22/94	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA, 1996, CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1, Science Jun 28;272(5270):1955-1958.
C02	Anderson et al., 1990, A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines subpopulation of CD8 ⁺ T lymphocytes, J. Immunol. 144:574-582.
C03	Barker et al., 1995, Effects of T _H 1 and T _H 2 cytokines on CD8 ⁺ cell response against human immunodeficiency virus: implications for long term survival, Proc. Natl. Acad. Sci. USA 92:11135-11139.
C04	Barré-Sinoussi F et al., 1983, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
C05	Biéniasz PD, Cullen BR, 1998, Chemokine receptors and human immunodeficiency virus infection, Front Biosci. Jan 1;3:D44-D58.
C06	Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA, 1996, The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry, Nature Aug 29; 382(6594):829-833.
C07	Brinchmann J et al., 1991, In vitro replication of HIV-1 in naturally infected CD4 ⁺ T cells is inhibited by rIFN α_2 and by a soluble factor secreted by activated CD8 ⁺ T cells, but not by rIFN β , rIFN δ , or recombinant tumor necrosis factor- α . J. Acquired Immune Deficiency Syndrome 4(5):480-488.
C08	Brinchmann J et al., 1989, Reliable isolation of human immunodeficiency virus from cultures of naturally infected CD4 ⁺ T cells, J. Virological Methods 25:293-300.
C09	Brinchmann J et al., 1990, CD8 ⁺ T cells inhibit HIV replication in naturally infected CD4 ⁺ T cells, evidence for a soluble inhibitor, J. Immunol. 144:2961-2966.
C10	Burgess R, ed., 1987, Protein Purification, Micro to Macro. Alan R. Liss, New York. pp. 17-26.

NY2: 1464589.2

C11	Cann AJ, ed., 1999, Virus Culture: A Practical Approach. Oxford University Press, New York, pp. 3-4.
C12	Carson K et al., 1994, Companies remain hopeful for vaccines for AIDS despite discouraging results. Gen. Engineering News 14:1,24,34.
C13	Castro B, 1991, Suppression of human immunodeficiency virus replication by CD8 ⁺ cells from infected and uninfected chimpanzees. Cellular Immunology 132:246-255.
C14	Chakrabarti S, Brechling K, Moss B, 1985, Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques, Mol Cell Biol. Dec; 5(12):3403-3409.
C15	Chang T et al., 2002, A soluble factor(s) secreted from CD8 ⁺ T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation, J. Virology 76(2):569-581.
C16	Chen et al., 1993, CD8 ⁺ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res. Hum. Retroviruses 9:1079-1086.
C17	Chen BK, Saksela K, Andino R, Baltimore D, 1994, Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses, J Virol. Feb;68(2):654-660.
C18	Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P, 1995, Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8 ⁺ T cells, Science Dec 15;270(5243):1811-1815.
C19	Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P, 1996, The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection, Nat Med. Nov; 2(11):1244-1247.
C20	Coligan JE et al., 1994, Current Protocols in Immunology, John Wiley & Sons, Inc., 7.19.1-7.21.9.
C21	Connor RI, Chen BK, Choe S, Landau NR, 1995, Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes, Virology Feb 1;206(2):935-944.
C22	Copeland K et al., 1996, CD8 ⁺ lymphocyte-mediated suppression of HIV-1 LTR-mediated transcription shows no correlation with clinical stage of disease or health status. XIth Int'l Con. AIDS, Vancouver, July 7-12:12 (Abs. Tu,A,395).
C23	Cullen B & Greene W, 1989, Regulatory pathways governing HIV replication, Cell 58:423-426.
C24	Dagleish et al., 1984, The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus, Nature 312:763-767.
C25	Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR, 1996, Identification of a major co-receptor for primary isolates of HIV-1, Nature Jun 20;381(6584):661-666.
C26	Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP, 1998, AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor, Nat Med. 1998 Jan;4(1):72-77.
C27	Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayan C, Maddon PJ, Koup RA, Moore JP, Paxton WA, HIV-1 entry into CD4 ⁺ cells is mediated by the chemokine receptor CC-CKR-5, Nature. 1996 Jun 20;381(6584):667-673.
C28	Earl PL, Hugin AW, Moss B, 1990, Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus, J Virol. May;64(5):2448-2451.
C29	Endres MJ et al., 1996, CD4-independent infection by HIV-2 is mediated by fusin/CXCR4, Cell Nov 15; 87(4):745-756.
C30	Fahey JL & Schooley R, 1992, Status of immune-based therapies in HIV infection and AIDS, Clin. Exp. Immunol. 88:1-5.
C31	Flexner C, Broyles SS, Earl P, Chakrabarti S, Moss B, 1988, Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses, Virology Oct 166(2):339-349.
C32	Fox, 1994, No winners against AIDS, Bio/Technology 12:128
C33	Gallo et al., 1984, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS, Science 224:500-503
C34	Goff S, Traktman P, Baltimore D, 1981, Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase, J Virol. Apr;38(1):239-248.
C35	Hara et al. 1991, Subtractive cDNA cloning using oligo(dT)30-latex and PCR: isolation of cDNA clones specific to undifferentiated human embryonal carcinoma cells, Nucleic Acids Res. Dec;19(25):7097-7104.
C36	Herfort et al. 1991, Simple and efficient subtractive hybridization screening, Biotechniques Nov;11(5):598, 600, 602-604.
C37	Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, Volsky DJ, 1991, Inhibition of HIV

		replication in acute and chronic infections in vitro by a Tat antagonist, Science Dec 20; 254(5039):1799-1802.
C38	✓	Janeway, CA et al., 1999, Immunobiology: The Immune System in Health and Disease. Current Biology Publications, Garland Publishing, London, pp. 231-234.
C39		Jung JU, Trimble JJ, King NW, Biesinger B, Fleckenstein BW, Desrosiers RC, 1991, Identification of transforming genes of subgroup A and C strains of Herpesvirus saimiri, Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7051-7055.
C40		Kannagi M, Masuda T, Hattori T, Kanoh T, Nasu K, Yamamoto N, Harada S, 1990, Interference with human immunodeficiency virus (HIV) replication by CD8 ⁺ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro, J Virol. Jul;64(7):3399-3406.
C41	✓	Kannagi M et al., 1988, Suppression of simian immunodeficiency virus replication in vitro by CD8 ⁺ lymphocytes, J Immunology 140(7):2237-2242.
C42	✓	Kinter A et al., 1995, Interleukin 2 induces CD8 ⁺ T cell-mediated suppression of human immunodeficiency virus replication in CD4 ⁺ T cells and this effect overrides its ability to stimulate virus expression, Proc. Natl. Acad. Sci. USA 92:10985-10989.
C43		Klatzmann et al., 1984, T-Lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV, Nature 312:767-768.
C44	✓	Kundu S et al., 1992, CD8 ⁺ CD11 ⁺ suppressor cells in HIV-infected asymptomatic patients: effect on HIV-specific cytotoxicity, Viral Immunol. Spring;5(1):15-25.
C45		Lacey SF, Weinhold KJ, Chen CH, McDanal C, Oei C, Greenberg ML, 1998, Herpesvirus saimiri transformation of HIV type 1 suppressive CD8 ⁺ lymphocytes from an HIV type 1-infected asymptomatic individual, AIDS Res Hum Retroviruses, 1998 Apr 10;14(6):521-531.
C46		Lacey SF, McDanal CB, Horuk R, Greenberg ML, 1997, The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8 ⁺ T cell suppression of syncytia-inducing strains of HIV-1, Proc Natl Acad Sci U S A. Sep 2;94(18):9842-9847.
C47	✓	Lacey SF et al., 1994, Herpesvirus saimiri transformation of suppressive CD8 ⁺ T-lymphocytes from a HIV ⁺ asymptomatic patient, AIDS Res. and Human Retroviruses 10(Suppl. 3):S70.
C48		Levy J et al., 1994, Mechanism of CD8 ⁺ cell suppression of HIV replication, J. Cell. Biochem. Suppl. 18B:111.
C49	✓	Mackewicz C et al., 1991, CD8 ⁺ lymphocytes from HIV-1 seropositive individuals block HIV replication in CD4 ⁺ lymphocytes by inhibiting viral RNA synthesis. Int. Conf. AIDS 7:74.
C50		Mackewicz C et al., 1991, CD8 ⁺ cell anti-HIV activity correlates with the clinical state of the infected individual. J. Clin. Invest. 87:1462-1466.
C51	✓	Mackewicz C et al., 1992, CD8 ⁺ cell anti-HIV activity: non-lytic suppression of virus replication. AIDS Res. Human Retroviruses 8:1039-1050.
C52		Maddon et al., 1986, The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain, Cell 47:333-348.
C53		Malim et al., 1988, Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes, Nature 335:181-183.
C54		Moore JP, Trkola A, Dragic T, 1997, Co-receptors for HIV-1 entry, Curr Opin Immunol. Aug;9(4):551-562.
C55		Oberlin E, Amara A, Bachelier F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B, 1996, The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1, Nature Aug 29; 382(6594):833-835.
C56	✓	Old R et al., 1989, Principles of Gene Manipulation, an Introduction to Genetic Engineering. Blackwell Scientific Publications, Oxford. pp. 137-139.
C57	✓	Pantaleo et al., 1992, Defective clonogenic potential of CD8 ⁺ T lymphocytes in patients with AIDS. expansion in vivo of nonclonogenic CD3 ⁺ CD8 ⁺ DR ⁺ CD25 ⁻ T Cell Population, J Immunol. 144:1702.
C58	✓	Powell J et al., 1990, CD8 ⁺ T-cell-induced inhibition of retroviral replication is mediated at the transcriptional level, Sym. nonhuman primate models AIDS 8:43.
C59	✓	Powell J et al., 1991, Regulation of immune activation/retroviral replication by CD8 ⁺ T cells, Ann. N.Y. Acad. Sci. USA 636:360-363.
C60	✓	Powell J et al., 1993, Inhibition of cellular activation of retroviral replication by CD8 ⁺ T cells derived from non-human primates, Clin. Exp. Immunol. 91:473-481.
C61	✓	Srivastava KK, Fernandez-Larsson R, Zinkus DM, Robinson HL, 1991, Human immunodeficiency virus type 1 NL4-3 replication in four T-cell lines: rate and efficiency of entry, a major determinant of permissiveness, J Virol. Jul;65(7):3900-3902.
C62	✓	Stein D et al., 1993, Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual, Clin. Infect. Dis. 17:749-771.
C63		Teich et al., 1984, Pathogenesis of lentivirus, in RNA Tumor Viruses, Weiss et al., eds., CSH Press, pp. 949-956.

Express Mail No.: EV 335 857 684 US

C64	Tomaras G & Greenberg M, 2001, CD8 ⁺ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I, Front. Biosci. 6:D575-598.
C65	Tomaras G & Greenberg M, 2001, Mechanisms for HIV-1 entry: current strategies to interfere with this step, Curr Infect Dis Rep. 2001 Feb;3(1):93-99.
C66	Tomaras G et al., 2000, CD8 ⁺ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression, Proc Natl Acad Sci U S A. Mar 28;97(7):3503-3508.
C67	Tsubota H et al., 1989, CD8 ⁺ CD4 ⁺ lymphocyte lines can harbor the AIDS virus in vitro, J Immunology 143(3):858-863.
C68	Tsubota H et al., 1989, A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes, J Exp. Med. 169:1421-1434.
C69	Walker et al., 1986, CD8 ⁺ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563-1566.
C70	Walker C & Levy J, 1989, A diffusible lymphokine produced by CD8 ⁺ T lymphocytes suppresses HIV replication, Immunology 66:628-630.
C71	Walker CM, Erickson AL, Hsueh FC, Levy JA, 1991, Inhibition of human immunodeficiency virus replication in acutely infected CD4 ⁺ cells by CD8 ⁺ cells involves a noncytotoxic mechanism, J Virol. 1991 Nov; 65(11):5921-5927.
C72	Walker C et al., 1989, CD8 ⁺ T lymphocyte control of HIV replication in cultured CD4 ⁺ cells varies among infected individuals, Cellular Immunology 119:470-475.
C73	Walker C et al., 1991, CD8 ⁺ cells from HIV-1-infected individuals inhibit acute infection by human and primate immunodeficiency viruses, Cellular Immunology 137:420-428.
C74	Wild C, Greenwell T, Matthews T, 1993, A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion, AIDS Res Hum Retroviruses, Nov;9(11):1051-1053.
C75	Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ, Martin MA, 1988, In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity, J Virol. Jan;62(1):139-147.
C76	Wiviott L et al., 1990, CD8 ⁺ lymphocytes suppress HIV production by autologous CD4 ⁺ cells without eliminating the infected cells from culture, Cellular Immunology 128:628-634.
C77	Wong-Staal F & Gallo R, 1985, Human T-lymphotropic retroviruses, Nature 317:395-403.
C78	Zhang L et al., 2002, Contribution of human α -defensin-1, -2, and -3 to the anti-HIV-1 activity of CD8 antiviral factor, Science 298(5595):995-1000.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.